Intravenous uterine leiomyomatosis extending into the right heart.

Aust N Z J Obstet Gynaecol

Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia.

Published: February 2011

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1479-828X.2010.01249.xDOI Listing

Publication Analysis

Top Keywords

intravenous uterine
4
uterine leiomyomatosis
4
leiomyomatosis extending
4
extending heart
4
intravenous
1
leiomyomatosis
1
extending
1
heart
1

Similar Publications

Background: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.

Methods: Patients received tremelimumab (intravenously, 75 mg, every four weeks (Q4W); four cycles max) plus durvalumab (intravenously, 1,500 mg, Q4W; 26 cycles max) and metronomic oral vinorelbine (40 mg, every three weeks (3QW)) until disease progression.

View Article and Find Full Text PDF

Background: A precise observation is that the cervix's solid tumors possess hypoxic regions where the oxygen concentration drops below 1.5%. Hypoxia negatively impacts the host's immune system and significantly diminishes the effectiveness of several treatments, including radiotherapy and chemotherapy.

View Article and Find Full Text PDF

Uterine smooth muscle neoplasms are a biologically and clinically heterogeneous group of tumors. Morphology is the cornerstone of pathologic diagnosis of these tumors, and most are readily classified as benign or malignant on the basis of routine histologic examination. However, rare subsets-including intravenous leiomyomatosis, benign metastasizing leiomyoma, and disseminated peritoneal leiomyomatosis-have a capacity for extrauterine spread despite benign cytomorphology.

View Article and Find Full Text PDF

Objective: This study aims to investigate the efficacy of continuous oxytocin administration after completion of routine oxytocin administration during the third stage of labor in patients with twin pregnancies delivered via cesarean delivery (CD).

Methods: This retrospective case-control study was conducted between April 2014 and March 2024, and it included 156 women with twin pregnancies. The oxytocin group included patients who were administered continuous oxytocin 2 IU/h until 24 hours after delivery after completion of oxytocin 5 IU intravenous injection immediately after delivery as the routine procedure.

View Article and Find Full Text PDF

A pregnant woman was brought to the emergency department looking starved and neglected. She was diagnosed with sepsis and started on intravenous antibiotics. She was also disoriented and hypernatremic.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!